Patents by Inventor Ghalib Alkhatib

Ghalib Alkhatib has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080241167
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: March 7, 2008
    Publication date: October 2, 2008
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Publication number: 20070087990
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: November 7, 2006
    Publication date: April 19, 2007
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward Berger, Philip Murphy, Christopher Broder, Paul Kennedy
  • Patent number: 7151087
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Resources
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Publication number: 20040259785
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: October 31, 2003
    Publication date: December 23, 2004
    Applicant: The Govt. of the USA, as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy
  • Publication number: 20030203450
    Abstract: The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (STRL33). STRL33 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. STRL33 plays a role in the membrane fusion step of HIV infection for both TCL-tropic and M-tropic variants of HIV. The invention provides STRL33 polypeptide and polynucleotide sequences encoding STRL33 polypeptide. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and STRL33 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against STRL33, isolated and purified peptide fragments of STRL33, and STRL33-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.
    Type: Application
    Filed: June 9, 2003
    Publication date: October 30, 2003
    Inventors: Joshua M. Farber, Fang Liao, Ghalib Alkhatib, Edward A. Berger
  • Publication number: 20030195348
    Abstract: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
    Type: Application
    Filed: May 15, 2003
    Publication date: October 16, 2003
    Applicants: The United States of America, represented by the Secretary,, Department of Health and Human Services
    Inventors: Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy